Business
OBD EpiSwitch® CiRT well received at ASCO 2022
OBD EpiSwitch® CiRT well received at ASCO 2022.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \n \n \n Oxford BioDynamics'\n \n \n simple blood test that predicts patient's response to Immune Checkpoint Inhibitors well received at\n \n \n ASCO 2022\n \n \n \n \n \n \n \n \n ·\n Immune Checkpoint Inhibitor (ICI) therapies are ineffective in up to 70% of patients receiving them, resulting in a critical need for early determination of patient response.\n \n \n ·\n EpiSwitch® CiRT is a first-of-its-kind precision medicine test that predicts a patient's likely response to ICI therapies. Accurate prediction of response is expected to save healthcare systems significant amounts due to the high cost of ICIs and subsequent adverse responses.\n \n \n ·\n The test has shown high sensitivity (93%), specificity (82%) and accuracy (85%) across 15 cancer indications where ICI treatments are available and has seen encouraging uptake by early adopters in the US since launch.\n \n \n ·\n OBD presented additional data on EpiSwitch CiRT at ASCO 2022 and met numerous practicing clinicians, pharma development teams, hospital systems and healthcare investors interested in the test.\n \n \n ·\n This simple blood test is now available to millions of cancer patients via their clinicians across the US at the website:\n \n \n myCiRT.com\n \n \n .\n \n \n Oxford, UK - 14 June 2022 -\n Oxford BioDynamics Plc (AIM: OBD, the Company),\n a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, presented additional data at ASCO 2022 on its flagship CiRT clinical assay to predict patient response to ICI therapies, which was well received.\n \n \n The EpiSwitch® Checkpoint inhibitor Response Test (CiRT) is a simple blood test available to US-based clinicians, enabling them to advise the millions of cancer patients facing the complex choice between powerful immunotherapy treatments, which might have low response rates and immune-related adverse events, and alternative treatment options.\n \n \n Launched in February 2022 as a Laboratory Developed Test (LDT),\n EpiSwitch CiRT\n is available for immediate clinical utilization in the US via the website: myCiRT.com.\n \n \n Interest in CiRT at ASCO was significant; OBD representatives held positive meetings with 11 pharma teams, two major US hospital networks\n ,\n National Cancer Institute-designated comprehensive cancer centers, as wel...